August 21, 2019
As the highest governing body, the Board of Directors at the major T1D non-profits are responsible for establishing the organization mission and values, setting the strategic direction, overseeing executive leadership, and allocating resources. Click here to read more.
August 12, 2019
This is the eighth annual review of executive compensation for the top diabetes non-profits. The review focuses on the ADA and JDRF, the largest diabetes fundraising organizations, but also includes data for Joslin and the Diabetes Research Institute Foundation (DRIF). Click here to read more.
August 6, 2019
This infographic provides a snapshot of how the ADA, one of the largest and most influential diabetes fundraising organizations in the U.S., uses its funds. Click here to read more.
July 15, 2019
This report provides an overview of type 1 diabetes research funding at the National Institutes of Health (NIH) in 2018. In preparing this report, the JDCA reviewed and categorized all NIH grants into three distinct categories: type 1 focused; type 2 focused; and general diabetes. Click here to read more.
June 20, 2019
Last week, the American Diabetes Association (ADA) released their audited financial statements for 2018. This is the seventh year that we have reviewed these financial documents and little has changed. Click here to read more.
June 11, 2019
The American Diabetes Association's 79th Scientific Sessions, the largest annual American diabetes research conference of the year, was held June 7-11 in San Francisco. Click here to read more and view conference highlights.
May 23, 2019
This report reviews the 11 active Practical Cure (PC) research projects underway in FDA approved human clinical trials. No projects have been abandoned since our last review in the 2018 State of the Cure and two new projects have been added to the list. Click here to read more.
May 21, 2019
This report outlines four key recommendations for the JDRF Board of Directors and the new CEO to consider during their planning process for the upcoming fiscal year. These recommendations are based upon the priorities and wishes of the T1D community as demonstrated in semi-annual JDCA surveys. Click here to read more.
May 13, 2019
A Practical Cure is any solution which minimizes the disruptive aspects of T1D, delivers a near-normal quality of life and has a chance to be available within the next 15 years. It is aligned with the wishes and desires of people who are currently living with type 1 diabetes. Click here to read more.
May 2, 2019
This is the seventh annual review of all active type 1 diabetes trials currently in human testing. This year, in addition to all clinical trials active in the US, we also included trials listed in the official registries of the EU, Australia, China, Japan, and India. Click here to read more.
March 25, 2019
This report examines JDRF's Payroll Expenses, which includes salaries, bonuses, and all other staffing expenses. Click here to read more.
March 14, 2019
This is the seventh annual survey-based report on the giving priorities of T1D donors. The key takeaway is the same as all prior years: the number one reason people make donations to diabetes charities and/or participate in fundraising activities such as walks and galas is to find a cure. Click here to read more.
March 7, 2019
This is a third in a series of reports on JDRF financials. The main takeaway is that JDRF administration cost for each dollar of actual research grants have increased 350 percent since 2008 while research grant spending is down 50 percent. Click here to read more.
February 21, 2019
This report provides an overview of JDRF's 2018 revenue and expenses, released last week. Based on publicly available tax and financial documents, it shows how JDRF generates its revenue and how it utilizes those funds. Click here to read more.
January 22, 2019
This report will review the evolution of encapsulation therapies and examine all companies currently developing encapsulation devices. Encapsulation is a form of cell transplantation, one of the four JDCA Practical Cure Pathways. Click here to read more.